Beyond the Lab: A Strategic Launchpad for Regenerative Therapies

Project Background & Objective

A pioneering biotech venture at the forefront of regenerative therapies and exosome innovation, led by a seasoned industry veteran with 23 years of experience, approached AND with a pressing need: to translate early scientific success into a clear, scalable growth strategy. What began as a focused ask quickly evolved into a deeper engagement around capital readiness, business structuring, and long-term strategic clarity.

Our engagement centered around:

• Bringing strategic clarity to capital deployment and the company's growth trajectory to support scaling efforts
• Developing core fundraising collateral, including shareholding restructuring, investor presentation, and information memorandum
• Addressing broader strategic and financial structuring needs that emerged beyond the initial mandate

Our Approach

Our comprehensive approach involved:

• Robust Financial Modelling: We developed a detailed financial model that mapped product-specific R&D costs, timelines, and risk profiles across their therapy pipeline.

• Dual-Track Development Strategy: Based on our financial analysis, we recommended a dual-track development strategy:

  • In-house development for therapies where intellectual property protection and secrecy were paramount
  • Joint collaborations for products where speed, cost-sharing, and clinical synergies could be unlocked

• Rationalized Implementation Roadmap: We helped rationalize their development roadmap, ensuring that the sequencing of therapies matched projected capital availability and investor appetite.

• Cap Table Restructuring: We worked on optimizing their capitalization table, including current investor holdings and ESOP (Employee Stock Option Plan) allocations, to align ownership with future talent retention and funding goals.

Our Impact

Our collaboration led to a strong, fundraising-ready toolkit that told a clear and compelling story positioning the client as a science-first innovator backed by solid business logic. Their team also gained strategic alignment through a clear, capital-efficient roadmap that connected their scientific vision to real growth.

As a result, the company stepped forward not just as an R&D leader, but as an investor-ready business with a scalable, structured plan.

At every stage AND acted as more than an advisor—we were a strategic partner. By closely collaborating with the client's leadership, we uncovered their core challenges and delivered solutions uniquely tailored to their growth stage and strategic needs.